Overview

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Status:
Completed

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Interferon-alpha
Ledipasvir
Peginterferon alfa-2a
Ribavirin